Key result
Pharmaco-invasive strategy cuts cardiogenic shock risk ~35% vs primary PCI in STEMI.
Why the study?
Recent articles on cardiogenic shock do not mention immediate fibrinolytic administration within a pharmacoinvasive strategy to prevent cardiogenic shock development after STEMI.
Does a pharmaco-invasive strategy reduce the incidence of cardiogenic shock within 30 days compared to primary PCI in patients with STEMI?
Meta-Analysis
Does a pharmaco-invasive strategy reduce the incidence of cardiogenic shock within 30 days compared to primary PCI in patients with STEMI?
A pharmaco-invasive strategy in STEMI patients significantly reduces the 30-day risk of developing cardiogenic shock compared to primary PCI, likely driven by higher rates of pre-PCI reperfusion.
Answers are grounded in this paper and cite their sources.
Supports pharmaco-invasive strategy over primary PCI to reduce cardiogenic shock in STEMI; confirms benefit across pooled randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vanhaverbeke et al. (2018) conducted a meta-analysis in ST-segment elevation acute myocardial infarction (STEMI). Pharmaco-invasive (PhI) strategy vs. Primary percutaneous coronary intervention (PPCI) was evaluated on Incidence of cardiogenic shock (CGS) (OR 0.65, 95% CI 0.46-0.92, p=0.02). A pharmaco-invasive strategy reduced the risk of developing cardiogenic shock compared to primary PCI in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: